 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration FDA has granted the Companys request for a Pre-IND Meeting to provide guidance regarding the Companys plan to study its drug candidate, WP1122, in a clinical trial for patients with COVID-19 the disease caused by the SARS-CoV-2 coronavirus. In addition, Moleculin provided a general update on its WP1122 development efforts. 